2023-06-29 23:55:09
The Sino-US led biotech company Insilico Medicine has used artificial intelligence to develop a drug to treat pulmonary fibrosis.
The drug called INS018_055 is the first drug developed by generative artificial intelligence, obviously with administration by a human being.
The drug is currently in phase 2 clinical trials. Alex Zhavoronkov, the company’s chief executive, reported that “this drug, which will be administered orally, will undergo the same rigorous testing to ensure efficacy and safety as traditionally discovered drugs.”
Employees’ Biggest Fear: Why Almost Everyone Is Asking to Train in AI
What is ChatGPT’s “grandma mode”: the feature that causes users to panic
How can AI be applied to medicine?
Artificial Intelligence has the ability to analyze massive volumes of information in order to quickly identify pharmaceutical targets, such as body proteins linked to certain diseases, and molecules that have the potential to be turned into drugs.
To develop the assistive drug, the company used technology to generate a new molecule capable of interacting with fibrosis.
Zhavoronkov concluded that “AI allows us to analyze massive amounts of data and find connections that human scientists might miss, and then ‘imagine’ entirely new molecules that can be turned into drugs.”
1688094964
#Doctors #worried #artificial #intelligence #developed #medicine
